
Eli Lilly and Co
NYSE:LLY

US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
721.432
958.4326
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.

Intrinsic Value
The intrinsic value of one
LLY
stock under the Base Case scenario is
375.83
USD.
Compared to the current market price of 813.48 USD,
Eli Lilly and Co
is
Overvalued by 54%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Eli Lilly and Co
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.

Valuation History
Historical valuation for LLY cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:

Despite the significant buzz around tirzepatide and other diabetes products, their high development and marketing costs could erode profitability if insurance reimbursement or pricing pressures intensify, particularly in today’s cost-conscious healthcare environment.
Eli Lilly’s reliance on blockbuster treatments like Trulicity exposes it to heightened competitive threats and patent cliffs—any new biosimilar entrants or patent challenges could substantially reduce revenue streams faster than anticipated.
R&D setbacks in the high-risk neurology and oncology segments could stall the pipeline’s momentum, especially if trials fail to demonstrate clear clinical benefits, jeopardizing future growth and investor confidence.
Tirzepatide’s rapid approvals and robust clinical outcomes in diabetes and obesity treatments position Eli Lilly to capture valuable market share in a high-growth therapeutic area, protecting long-term revenue streams.
A well-diversified pipeline, including Alzheimer’s candidates like donanemab, aligns with major unmet clinical needs and underscores Eli Lilly’s capacity to deliver innovative treatments that command premium pricing.
The company’s strategic partnerships and acquisitions, such as those aimed at expanding the oncology platform, strengthen its pipeline while distributing R&D risk across multiple promising therapeutic classes.

Revenue & Expenses Breakdown
Eli Lilly and Co
Balance Sheet Decomposition
Eli Lilly and Co
Current Assets | 32.7B |
Cash & Short-Term Investments | 3.4B |
Receivables | 13.3B |
Other Current Assets | 16B |
Non-Current Assets | 46B |
Long-Term Investments | 3.2B |
PP&E | 17.1B |
Intangibles | 11.9B |
Other Non-Current Assets | 13.7B |
Current Liabilities | 28.4B |
Accounts Payable | 3.2B |
Accrued Liabilities | 13.6B |
Other Current Liabilities | 11.5B |
Non-Current Liabilities | 36.1B |
Long-Term Debt | 28.5B |
Other Non-Current Liabilities | 7.6B |
Free Cash Flow Analysis
Eli Lilly and Co
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Eli Lilly and Co
Revenue
|
45B
USD
|
Cost of Revenue
|
-8.4B
USD
|
Gross Profit
|
36.6B
USD
|
Operating Expenses
|
-19.6B
USD
|
Operating Income
|
17B
USD
|
Other Expenses
|
-6.5B
USD
|
Net Income
|
10.6B
USD
|
LLY Profitability Score
Profitability Due Diligence
Eli Lilly and Co's profitability score is 75/100. The higher the profitability score, the more profitable the company is.

Score
Eli Lilly and Co's profitability score is 75/100. The higher the profitability score, the more profitable the company is.
LLY Solvency Score
Solvency Due Diligence
Eli Lilly and Co's solvency score is 65/100. The higher the solvency score, the more solvent the company is.

Score
Eli Lilly and Co's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LLY Price Targets Summary
Eli Lilly and Co
According to Wall Street analysts, the average 1-year price target for
LLY
is 1 015.76 USD
with a low forecast of 707 USD and a high forecast of 1 249.5 USD.
Dividends
Current shareholder yield for LLY is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
LLY
stock under the Base Case scenario is
375.83
USD.
Compared to the current market price of 813.48 USD,
Eli Lilly and Co
is
Overvalued by 54%.